Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offerGlobeNewsWire • 10/22/25
Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRMLBusiness Wire • 10/06/25
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)PRNewsWire • 09/15/25
TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRMLBusiness Wire • 09/11/25
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to PipelineZacks Investment Research • 09/10/25
Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fitInvezz • 09/09/25
TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to ShareholdersBusiness Wire • 09/09/25
Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion rangeMarket Watch • 09/09/25
Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public ShareholdersBusiness Wire • 09/09/25
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)GlobeNewsWire • 09/09/25
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology CongressGlobeNewsWire • 08/31/25
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should KnowZacks Investment Research • 08/15/25
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/13/25
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025GlobeNewsWire • 05/19/25